PPA, PHA and Su-PS skin tests were performed on 152 urogenital malignancy patients and the results obtained were analysed in terms of clinical course. The survival rate of 86 patients showing a positive response to the PPD skin test was significantly higher (P less than 0.005) than that of 65 patients showing a negative response to the PPD skin test. Among the 33 renal tumor patients, the positive rate of the 10 patients with stage I tumors to PPD skin test was significantly higher (P less than 0.05) than that of the 13 patients with stage IV tumors. In 68 bladder tumor patients, the response rate to PPD skin test in 47 patients with a low stage tumor was significantly high (P less than 0.05) compared with that in 21 patients with a high stage tumor. Out of 47 patients who died during the 84-month observation period, 10 (21.7%) and 3 (13.3%) showed a response change from negative to positive, in the PPD test and Su-PS test, respectively. It was assumed that 32 of the 46 patients (69.6%), 4 of the 6 patients (66.7%) and 17 of the 23 patients (73.9%) submitted to the PPD, PHA and Su-PS tests, respectively, showed a negative response at the time of their death.